Document is current
Any future updates will be listed below
-
Authors
Shehaj, Ina https://orcid.org/0009-0001-3304-5040
Krajnak, Slavomir
Rad, Morva Tahmasbi
Gasimli, Bahar
Hasenburg, Annette
Karn, Thomas
Schmidt, Marcus
Müller, Volker
Becker, Sven
Gasimli, Khayal
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 26 December 2023
Accepted: 13 March 2024
First Online: 3 April 2024
Declarations
:
: Listed below are the personal conflicts of interest of the (co-)authors. The funders listed were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. S. Krajnak received speaker honoraria from Roche Pharma AG and Novartis Pharma GmbH Germany, research funding from Novartis Pharma GmbH Germany and travel reimbursement from PharmaMar and Novartis Pharma GmbH Germany. A. Hasenburg received honoraria from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup!GmbH, Tesaro Bio Germany GmbH. She is a member of the advisory board of AstraZeneca, GSK, LEO Pharma, PharmaMar, Promedicis GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH, MSD Sharp&Dohme GmbH. M. Schmidt reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, Marcus Schmidt has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1 issued. All other authors declare that they have no conflicts of interest.
